The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic …
…, M Ceyhan, H Christensen, Y Climent… - Expert review of …, 2019 - Taylor & Francis
Introduction: The 2018 Global Meningococcal Initiative (GMI) meeting focused on evolving
invasive meningococcal disease (IMD) epidemiology, surveillance, and protection strategies …
invasive meningococcal disease (IMD) epidemiology, surveillance, and protection strategies …
SARS-CoV-2 RBD-Tetanus toxoid conjugate vaccine induces a strong neutralizing immunity in preclinical studies
…, Y Ramos, LJ González, Y Climent… - ACS Chemical …, 2021 - ACS Publications
Controlling the global COVID-19 pandemic depends, among other measures, on developing
preventive vaccines at an unprecedented pace. Vaccines approved for use and those in …
preventive vaccines at an unprecedented pace. Vaccines approved for use and those in …
Molecular aspects concerning the use of the SARS-CoV-2 receptor binding domain as a target for preventive vaccines
…, F Paquet, S Fernandez, Y Climent… - ACS central …, 2021 - ACS Publications
The development of recombinant COVID-19 vaccines has resulted from scientific progress
made at an unprecedented speed during 2020. The recombinant spike glycoprotein monomer…
made at an unprecedented speed during 2020. The recombinant spike glycoprotein monomer…
[HTML][HTML] A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles
D Santana-Mederos, R Perez-Nicado, Y Climent… - RSC chemical …, 2022 - pubs.rsc.org
SARS-CoV-2 infection is mediated by the interaction of the spike glycoprotein trimer via its
receptor-binding domain (RBD) with the host’s cellular receptor. Vaccines seek to block this …
receptor-binding domain (RBD) with the host’s cellular receptor. Vaccines seek to block this …
Clonal Distribution of Disease-Associated and Healthy Carrier Isolates of Neisseria meningitidis between 1983 and 2005 in Cuba
In response to epidemic levels of serogroup B meningococcal disease in Cuba during the
1980s, the VA-MENGOC-BC vaccine was developed and introduced into the National Infant …
1980s, the VA-MENGOC-BC vaccine was developed and introduced into the National Infant …
Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate
M Delgado, D Yero, O Niebla, S González, Y Climent… - Vaccine, 2007 - Elsevier
Polysaccharide-based vaccines for serogroup B Neisseria meningitidis have failed to induce
protective immunity. As a result, efforts to develop vaccines for serogroup B meningococcal …
protective immunity. As a result, efforts to develop vaccines for serogroup B meningococcal …
Identification of new meningococcal serogroup B surface antigens through a systematic analysis of neisserial genomes
The difficulty of inducing an effective immune response against the Neisseria meningitidis
serogroup B capsular polysaccharide has lead to the search for vaccines for this serogroup …
serogroup B capsular polysaccharide has lead to the search for vaccines for this serogroup …
[HTML][HTML] A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open …
…, R Ochoa-Azze, Y Climent-Ruiz… - The Lancet Regional …, 2021 - thelancet.com
Background As a first step towards a vaccine protecting COVID-19 convalescents from
reinfection, we evaluated FINLAY-FR-1A vaccine in a clinical trial. Methods Thirty COVID-19 …
reinfection, we evaluated FINLAY-FR-1A vaccine in a clinical trial. Methods Thirty COVID-19 …
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials
…, S Fernandez-Castillo, Y Climent-Ruiz… - Vaccine, 2022 - Elsevier
Background SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant
RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we …
RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we …
[HTML][HTML] Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor …
…, S Fernandez-Castillo, Y Climent-Ruiz… - International Journal of …, 2023 - Elsevier
Objectives To evaluate a heterologous vaccination scheme in children 3-18 years old (y/o)
combining two SARS-CoV-2r- receptor binding domain (RBD)protein vaccines. Methods A …
combining two SARS-CoV-2r- receptor binding domain (RBD)protein vaccines. Methods A …